Logo
  • Home
  • AI Agent
  • Annotations
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy
  • Get the full experience

    We save the real magic for signed-in users.

ARQ US​
HomeStock ScreenerDocument SearchChartingWatchlistsRecent Filings

Arq, Inc.(ARQ US)

$2.86-0.185.92%Ext:$3.09+0.238.00%(Market Closed · 00:45:13 UTC)
Ask AI
ProfileEntity StructureAll DocumentsFinancialsChartingShort InterestEmployees

Overview

ProfileEntity Structure

Documents

SEC Filings
Logo
  • Home
  • AI Agent
  • Annotations
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy
  • Get the full experience

    We save the real magic for signed-in users.

ARQ US​
HomeStock ScreenerDocument SearchChartingWatchlistsRecent Filings

Arq, Inc.(ARQ US)

$2.86-0.185.92%Ext:$3.09+0.238.00%(Market Closed · 00:45:13 UTC)
Ask AI
ProfileEntity StructureAll DocumentsFinancialsChartingShort InterestEmployees

Overview

ProfileEntity Structure

Documents

SEC Filings
All Documents

Financials & Metrics

FinancialsChartingShort InterestEmployees
All Documents

Financials & Metrics

FinancialsChartingShort InterestEmployees

Arq, Inc. — Company Profile

Operating throughout North America, Arq, Inc. is a specialized manufacturer of activated carbon materials. Their product range encompasses various types of activated carbon, specifically granular, powdered, and colloidal forms. Additionally, they provide Arq Powder Wetcake, which is a finely processed, low-ash particle originating from coal waste, along with additives formulated for managing air pollution. These versatile products find application in numerous sectors, including water purification, remediation of contaminated groundwater, enhancing soil composition, controlling atmospheric discharges, and as components in asphalt mixtures. Established in 1996, the company rebranded as Arq, Inc. in February 2024, having previously been known as Advanced Emissions Solutions, Inc. Its corporate headquarters are located in Greenwood Village, Colorado.

Exchange
UQ
CEO
Robert E. Rasmus
Headquarters
Greenwood Village, CO, US
IPO Date
Jan 23, 2004
Employees
202
Website
www.arq.com

Key Metrics

Price
$1.94
Market Cap
$83.28M
Revenue (TTM)
$29.05M
Net Income (TTM)
$-842000.00
EPS (TTM)
-0.02
P/E (TTM)
-1.55
P/B (TTM)
0.50
Dividend Yield
8.33%
ROE (TTM)
-0.50%
ROA (TTM)
-0.36%
Operating Margin
-3.38%
Beta
1.47

Dividends

Last Dividend
$0.25
Last Yield
0.08%

Summary

Operating throughout North America, Arq, Inc. is a specialized manufacturer of activated carbon materials. Their product range encompasses various types of activated carbon, specifically granular, powdered, and colloidal forms. Additionally, they provide Arq Powder Wetcake, which is a finely processed, low-ash particle originating from coal waste, along with additives formulated for managing air pollution. These versatile products find application in numerous sectors, including water purification, remediation of contaminated groundwater, enhancing soil composition, controlling atmospheric discharges, and as components in asphalt mixtures. Established in 1996, the company rebranded as Arq, Inc. in February 2024, having previously been known as Advanced Emissions Solutions, Inc. Its corporate headquarters are located in Greenwood Village, Colorado.

Website
www.arq.com
Location
Greenwood Village, CO, US
Phone720 598 3500
Employees202
CEORobert E. Rasmus
IPO DateJan 23, 2004

Latest Documents

SEC Filings(806)

Expand
  • 8-KResults of Operations and Financial Condition4 Nov
  • 10-QQ3ended 30 Sept 20264 Nov
  • S-8Registration statement (employee benefit plan)17 Sep
  • Form 4Steinmetz Shimon10 Sep
  • Form 4Steinmetz Shimon9 Sep
  • Form 4Steinmetz Shimon8 Sep
  • Form 4Owino Peter Oluoch3 Sep
  • 8-KDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers28 Aug
  • Form 4Wong Joseph M18 Aug
  • 8-KResults of Operations and Financial Condition10 Aug
  • 10-QQ2ended 30 Jun 202610 Aug
  • Form 4Steinmetz Shimon4 Aug
  • Form 4Smith Claiborne Benson4 Aug
  • Form 4Wong Joseph M4 Aug
  • Form 3Steinmetz Shimon4 Aug
  • Form 4Rasmus Robert E.23 Jul
  • 8-KDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers23 Jul
  • Form 4EICHER CAROL S6 Jul
  • Form 4Blank Jeremy6 Jul
  • Form 4Bergman Laurie6 Jul

News

  • Water Tower Research Announces Inaugural WTR Forum Series Event, "CLEAN AIR AND WATER: Feedstock, Filtration, and PFAS Solutions," December 10, 202618 Nov
  • Arq: Plenty Of Upside After Best Quarter In Recent Years - Buy (Rating Upgrade)7 Nov
  • Arq, Inc. (ARQ) Q3 2026 Earnings Call Transcript5 Nov
  • ARQ (NASDAQ:ARQ) versus Cabot (NYSE:CBT) Head-To-Head Survey5 Nov
  • Arq, Inc. (ARQ) Tops Q3 Earnings and Revenue Estimates4 Nov
  • Arq Reports Third Quarter 2026 Results4 Nov
  • ARQ (ARQ) Projected to Release Earnings on Wednesday2 Nov
  • Arq Schedules Third Quarter 2026 Earnings Conference Call13 Oct
  • Contrasting Mativ (NYSE:MATV) & ARQ (NASDAQ:ARQ)11 Oct
  • Comparing ARQ (NASDAQ:ARQ) & Linde (NASDAQ:LIN)10 Oct
  • Argo's August Oil Production9 Oct
  • Arq Publishes 2025 Sustainability Report30 Sep
  • Argo's June Oil Production18 Sep
  • Argo's July Oil Production18 Sep
  • Arq to Attend Upcoming Investor Conferences16 Sep
  • Argo Completes Sale of Rockstar Gold Project Royalty for $250,00011 Sep
  • Arq Appoints Peter Owino as Chief Accounting Officer28 Aug
  • Gabelli To Host 4th Annual PFAS Symposium24 Aug
  • Arq: Legacy Powdered Activated Carbon Business Back In Focus - Hold23 Aug

Mentions in Filings

  • … VEF, right ventricular ejection fraction; AAD, anti-arrhythmia drug. Sources: (1) Cadrin-Tourigny J, et al. Eur Heart J. 2022;43(32):e1-e9. (2) Gasperetti A, et al. JAMA Cardiol. 2022;7(4):378-385; (3) Elias Neto J, et al. <strong>Arq</strong> Bras Cardiol. 2019;112(1):91-103; (4) Wang W, et al. Europace. 2019;21(1):9-21. Measurements of arrhythmia and function have been assessed within individuals and across ACM populations Patient-reported outcomes Treatment es …
    Lexeo Therapeutics, Inc.Arq, Inc.·EX-99.2 - 8-K - Results of Operations and Financial Condition·Q4 26·16 Nov
  • … orted development of the dynamic flow model used for the Reserve Estimate, described in Section 12.0. To ensure consistency and accuracy in elevation control, a high-precision topographic survey was completed by the independent firm <strong>Arq</strong>&Top between September and October 2024. This survey harmonized piezometric and topographic elevation datasets. Evaluation of the saline interface was further supported by targeted exploration datasets, including:
    Lithium Argentina AGArq, Inc.·EX-99.1 - 6-K - EXHIBIT 99.1·Q3 26·6 Nov
  • … mated, at which point the Company will determine whether the payment should be expensed or capitalized depending on whether the IPR&D has achieved market acceptance. Under the terms of the Share Purchase Agreement, the Company will develop and seek FDA approval of a therapeutic product containing <strong>ARQ</strong>-234 for an atopic dermatitis indication, and if FDA approval of ARQ-234 is obtained by the Company, to commercially launch it in the United States.
    Arcutis Biotherapeutics, Inc.Arq, Inc.·10-Q - Quarterly report Q3·Q3 26·4 Nov
  • … nroll a Phase 2 trial evaluating the safety and efficacy of ZORYVE foam 0.3% in the treatment of cutaneous adverse events due to checkpoint inhibitors. •The Company continues to enroll patients in the Phase 1a/1b study of <strong>ARQ</strong>-234, a potent and highly selective checkpoint agonist of the CD200 receptor, for the treatment of atopic dermatitis and has progressed to the multiple ascending dose portion of the trial. Corporate Updates •Appointed Rob …
    Arcutis Biotherapeutics, Inc.Arq, Inc.·EX-99.1 - 8-K - Results of Operations and Financial Condition·Q4 26·4 Nov
  • … A-TEX FINANCIAL SERVICES LLC BENCHMARK MORTGAGE | 1 | 435 | 0 | | | | | | | | | | | | | | | | | | | | | | ARK-LA-TEX FINANCIAL SERVICES LLC DBA BENCHMARK MORTGAGE | 3 | 1,923 | 0 | | | | | | | | | | | | | | | | | | | | | | <strong>ARQ</strong> LENDING INC | 1 | 686 | 0 | | | | | | | | | | | | | | | | | | | | | | ATLANTIC BAY MORTGAGE GROUP L L C | 2 | 1,293 | 0 | | | | | | | | | | | | | | | | | | | | | | ATLANTIC BAY MORTGAGE GROUP LLC | 6 | 3,691 | 0 | | | | | | …
    FEDERAL HOME LOAN MORTGAGE CORPArq, Inc.·ABS-15G/A - FILE 7 OF 9·Q3 26·13 Nov
  • … | | | | | | | | | | | | | | | | | | ARK MORTGAGE INC | 1 | 807 | 0 | | | | | | | | | | | | | | | | | | | | | | ARK-LA-TEX FINANCIAL SERVICES LLC BENCHMARK MORTGAGE | 1 | 455 | 0 | | | | | | | | | | | | | | | | | | | | | | <strong>ARQ</strong> LENDING INC | 1 | 657 | 0 | | | | | | | | | | | | | | | | | | | | | | ARTISANS' BANK | 1 | 329 | 0 | | | | | | | | | | | | | | | | | | | | | | ARVEST BANK | 12 | 5,690 | 1 | | | | | | | | | | | | | | | | | | | | | | ASSOCIA …
    FEDERAL HOME LOAN MORTGAGE CORPArq, Inc.·ABS-15G/A - FILE 4 OF 9·Q3 26·13 Nov

Key Stats

Trading

Px/Chg 1D$1.94 / +2.65%
Prev Close$2.30
% of 52Wk H28.70%
Avg Volume707.36K
Beta1.47
Mkt Cap83.28M
FD Mkt Cap94.87M

Float

Shrs Out/Float42.93M / 31.77M
Short Float0.02%
Days to Cover1.00
Stock Repurchased$200.00K

Current Valuation

EV116.93M
EV/EBITDA-2.89
EV/Sales0.96
P/B0.50
P/S0.68
FCF Yield-0.72%
ROE-0.50%
ROA-0.36%
Current Ratio1.02

Dividend

Cash$0.25
Yield8.33%
Yield (TTM)8.33%

Estimates

P/E-1.55
Est P/E0.00
Est EPS-0.02
Est PEG0.00

Valuation

Metric5Yr AvgMar '23Mar '24May '25May '26Oct '26
PRICE-BASED RATIOS
Price / Earnings-30.20-4.22-15.40-29.99-1.97-99.41
Price / Sales1.980.371.901.413.352.88
Price / Book Value0.620.271.060.710.590.50
Price / Free Cash Flow-34.65-2.51-4.27-2.05-24.46-139.98
ENTERPRISE VALUE METRICS
Enterprise Value115.9-16.3175.0174.1129.5117.4
Enterprise Value / Sales2.33-0.161.761.604.404.04
Enterprise Value / EBITDA53.308.36119.7626.46-2.81114.73
Enterprise Value / EBIT-36.431.95-19.27-86.34-2.62-75.87

Financials

Full Financials
Millions USD5Yr CAGR (%)Dec '21Dec '22Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue4.7%100.3103.099.2109.0120.3
Gross Income-86.5%34.722.531.939.433.5
EBITDA—85.5-2.01.56.6-38.4
EBIT—77.6-8.4-9.1-2.0-50.1
Net Income—60.4-8.9-12.2-5.1-52.6
EPS (Diluted)—3.27-0.48-0.42-0.14-1.27
BALANCE SHEET
Cash & ST Inv-46.3%78.866.445.413.56.6
Total Assets5.6%185.4181.2235.5284.4230.6
Total Liabilities13.2%38.141.257.167.162.6
Total Shareholder Equity3.3%147.3140.0178.4217.3168.0
CASH FLOW
Net Operating Cash Flow—26.0-6.1-16.710.5-2.5
Cap Ex8.4%-6.2-8.9-27.5-85.2-8.6
Free Cash Flow—19.8-15.0-44.2-74.7-11.1

Enterprise Value Bridge

Millions USD18 Nov '26
Price (As of 18 Nov '26)2.86
Basic Shares42.93
Market Cap122.6
Diluted Shares42.95
Fully Diluted Shares Outstanding42.95
Fully Diluted Market Cap122.6
+Consolidated Debt16.6
−In-the-Money Convertible Debt—
+Capital Leases7.6
+Operating Leases—
−Cash & Equivalents-7.8
−Short-term Investments-
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest-
+Pension Liabilities—
Enterprise Value131.4

Segment data

Revenue

by Geography

  • United States93%
  • Canada7%

Related companies

Element Solutions Inc

ESI US

Cabot Corp

CBT US

Wd 40 Co

WDFC US

Flotek Industries Inc/cn/

FTK US

ASP Isotopes Inc.

ASPI US

Orion S.A.

OEC US

NEXT-ChemX Corporation.

CHMX US

PV Nano Cell, Ltd.

PVNNF US

Versum Materials, Inc.

VSM XS

Arq, Inc. — Company Profile

Operating throughout North America, Arq, Inc. is a specialized manufacturer of activated carbon materials. Their product range encompasses various types of activated carbon, specifically granular, powdered, and colloidal forms. Additionally, they provide Arq Powder Wetcake, which is a finely processed, low-ash particle originating from coal waste, along with additives formulated for managing air pollution. These versatile products find application in numerous sectors, including water purification, remediation of contaminated groundwater, enhancing soil composition, controlling atmospheric discharges, and as components in asphalt mixtures. Established in 1996, the company rebranded as Arq, Inc. in February 2024, having previously been known as Advanced Emissions Solutions, Inc. Its corporate headquarters are located in Greenwood Village, Colorado.

Exchange
UQ
CEO
Robert E. Rasmus
Headquarters
Greenwood Village, CO, US
IPO Date
Jan 23, 2004
Employees
202
Website
www.arq.com

Key Metrics

Price
$1.94
Market Cap
$83.28M
Revenue (TTM)
$29.05M
Net Income (TTM)
$-842000.00
EPS (TTM)
-0.02
P/E (TTM)
-1.55
P/B (TTM)
0.50
Dividend Yield
8.33%
ROE (TTM)
-0.50%
ROA (TTM)
-0.36%
Operating Margin
-3.38%
Beta
1.47

Dividends

Last Dividend
$0.25
Last Yield
0.08%

Summary

Operating throughout North America, Arq, Inc. is a specialized manufacturer of activated carbon materials. Their product range encompasses various types of activated carbon, specifically granular, powdered, and colloidal forms. Additionally, they provide Arq Powder Wetcake, which is a finely processed, low-ash particle originating from coal waste, along with additives formulated for managing air pollution. These versatile products find application in numerous sectors, including water purification, remediation of contaminated groundwater, enhancing soil composition, controlling atmospheric discharges, and as components in asphalt mixtures. Established in 1996, the company rebranded as Arq, Inc. in February 2024, having previously been known as Advanced Emissions Solutions, Inc. Its corporate headquarters are located in Greenwood Village, Colorado.

Website
www.arq.com
Location
Greenwood Village, CO, US
Phone720 598 3500
Employees202
CEORobert E. Rasmus
IPO DateJan 23, 2004

Latest Documents

SEC Filings(806)

Expand
  • 8-KResults of Operations and Financial Condition4 Nov
  • 10-QQ3ended 30 Sept 20264 Nov
  • S-8Registration statement (employee benefit plan)17 Sep
  • Form 4Steinmetz Shimon10 Sep
  • Form 4Steinmetz Shimon9 Sep
  • Form 4Steinmetz Shimon8 Sep
  • Form 4Owino Peter Oluoch3 Sep
  • 8-KDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers28 Aug
  • Form 4Wong Joseph M18 Aug
  • 8-KResults of Operations and Financial Condition10 Aug
  • 10-QQ2ended 30 Jun 202610 Aug
  • Form 4Steinmetz Shimon4 Aug
  • Form 4Smith Claiborne Benson4 Aug
  • Form 4Wong Joseph M4 Aug
  • Form 3Steinmetz Shimon4 Aug
  • Form 4Rasmus Robert E.23 Jul
  • 8-KDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers23 Jul
  • Form 4EICHER CAROL S6 Jul
  • Form 4Blank Jeremy6 Jul
  • Form 4Bergman Laurie6 Jul

News

  • Water Tower Research Announces Inaugural WTR Forum Series Event, "CLEAN AIR AND WATER: Feedstock, Filtration, and PFAS Solutions," December 10, 202618 Nov
  • Arq: Plenty Of Upside After Best Quarter In Recent Years - Buy (Rating Upgrade)7 Nov
  • Arq, Inc. (ARQ) Q3 2026 Earnings Call Transcript5 Nov
  • ARQ (NASDAQ:ARQ) versus Cabot (NYSE:CBT) Head-To-Head Survey5 Nov
  • Arq, Inc. (ARQ) Tops Q3 Earnings and Revenue Estimates4 Nov
  • Arq Reports Third Quarter 2026 Results4 Nov
  • ARQ (ARQ) Projected to Release Earnings on Wednesday2 Nov
  • Arq Schedules Third Quarter 2026 Earnings Conference Call13 Oct
  • Contrasting Mativ (NYSE:MATV) & ARQ (NASDAQ:ARQ)11 Oct
  • Comparing ARQ (NASDAQ:ARQ) & Linde (NASDAQ:LIN)10 Oct
  • Argo's August Oil Production9 Oct
  • Arq Publishes 2025 Sustainability Report30 Sep
  • Argo's June Oil Production18 Sep
  • Argo's July Oil Production18 Sep
  • Arq to Attend Upcoming Investor Conferences16 Sep
  • Argo Completes Sale of Rockstar Gold Project Royalty for $250,00011 Sep
  • Arq Appoints Peter Owino as Chief Accounting Officer28 Aug
  • Gabelli To Host 4th Annual PFAS Symposium24 Aug
  • Arq: Legacy Powdered Activated Carbon Business Back In Focus - Hold23 Aug

Mentions in Filings

  • … VEF, right ventricular ejection fraction; AAD, anti-arrhythmia drug. Sources: (1) Cadrin-Tourigny J, et al. Eur Heart J. 2022;43(32):e1-e9. (2) Gasperetti A, et al. JAMA Cardiol. 2022;7(4):378-385; (3) Elias Neto J, et al. <strong>Arq</strong> Bras Cardiol. 2019;112(1):91-103; (4) Wang W, et al. Europace. 2019;21(1):9-21. Measurements of arrhythmia and function have been assessed within individuals and across ACM populations Patient-reported outcomes Treatment es …
    Lexeo Therapeutics, Inc.Arq, Inc.·EX-99.2 - 8-K - Results of Operations and Financial Condition·Q4 26·16 Nov
  • … orted development of the dynamic flow model used for the Reserve Estimate, described in Section 12.0. To ensure consistency and accuracy in elevation control, a high-precision topographic survey was completed by the independent firm <strong>Arq</strong>&Top between September and October 2024. This survey harmonized piezometric and topographic elevation datasets. Evaluation of the saline interface was further supported by targeted exploration datasets, including:
    Lithium Argentina AGArq, Inc.·EX-99.1 - 6-K - EXHIBIT 99.1·Q3 26·6 Nov
  • … mated, at which point the Company will determine whether the payment should be expensed or capitalized depending on whether the IPR&D has achieved market acceptance. Under the terms of the Share Purchase Agreement, the Company will develop and seek FDA approval of a therapeutic product containing <strong>ARQ</strong>-234 for an atopic dermatitis indication, and if FDA approval of ARQ-234 is obtained by the Company, to commercially launch it in the United States.
    Arcutis Biotherapeutics, Inc.Arq, Inc.·10-Q - Quarterly report Q3·Q3 26·4 Nov
  • … nroll a Phase 2 trial evaluating the safety and efficacy of ZORYVE foam 0.3% in the treatment of cutaneous adverse events due to checkpoint inhibitors. •The Company continues to enroll patients in the Phase 1a/1b study of <strong>ARQ</strong>-234, a potent and highly selective checkpoint agonist of the CD200 receptor, for the treatment of atopic dermatitis and has progressed to the multiple ascending dose portion of the trial. Corporate Updates •Appointed Rob …
    Arcutis Biotherapeutics, Inc.Arq, Inc.·EX-99.1 - 8-K - Results of Operations and Financial Condition·Q4 26·4 Nov
  • … A-TEX FINANCIAL SERVICES LLC BENCHMARK MORTGAGE | 1 | 435 | 0 | | | | | | | | | | | | | | | | | | | | | | ARK-LA-TEX FINANCIAL SERVICES LLC DBA BENCHMARK MORTGAGE | 3 | 1,923 | 0 | | | | | | | | | | | | | | | | | | | | | | <strong>ARQ</strong> LENDING INC | 1 | 686 | 0 | | | | | | | | | | | | | | | | | | | | | | ATLANTIC BAY MORTGAGE GROUP L L C | 2 | 1,293 | 0 | | | | | | | | | | | | | | | | | | | | | | ATLANTIC BAY MORTGAGE GROUP LLC | 6 | 3,691 | 0 | | | | | | …
    FEDERAL HOME LOAN MORTGAGE CORPArq, Inc.·ABS-15G/A - FILE 7 OF 9·Q3 26·13 Nov
  • … | | | | | | | | | | | | | | | | | | ARK MORTGAGE INC | 1 | 807 | 0 | | | | | | | | | | | | | | | | | | | | | | ARK-LA-TEX FINANCIAL SERVICES LLC BENCHMARK MORTGAGE | 1 | 455 | 0 | | | | | | | | | | | | | | | | | | | | | | <strong>ARQ</strong> LENDING INC | 1 | 657 | 0 | | | | | | | | | | | | | | | | | | | | | | ARTISANS' BANK | 1 | 329 | 0 | | | | | | | | | | | | | | | | | | | | | | ARVEST BANK | 12 | 5,690 | 1 | | | | | | | | | | | | | | | | | | | | | | ASSOCIA …
    FEDERAL HOME LOAN MORTGAGE CORPArq, Inc.·ABS-15G/A - FILE 4 OF 9·Q3 26·13 Nov

Key Stats

Trading

Px/Chg 1D$1.94 / +2.65%
Prev Close$2.30
% of 52Wk H28.70%
Avg Volume707.36K
Beta1.47
Mkt Cap83.28M
FD Mkt Cap94.87M

Float

Shrs Out/Float42.93M / 31.77M
Short Float0.02%
Days to Cover1.00
Stock Repurchased$200.00K

Current Valuation

EV116.93M
EV/EBITDA-2.89
EV/Sales0.96
P/B0.50
P/S0.68
FCF Yield-0.72%
ROE-0.50%
ROA-0.36%
Current Ratio1.02

Dividend

Cash$0.25
Yield8.33%
Yield (TTM)8.33%

Estimates

P/E-1.55
Est P/E0.00
Est EPS-0.02
Est PEG0.00

Valuation

Metric5Yr AvgMar '23Mar '24May '25May '26Oct '26
PRICE-BASED RATIOS
Price / Earnings-30.20-4.22-15.40-29.99-1.97-99.41
Price / Sales1.980.371.901.413.352.88
Price / Book Value0.620.271.060.710.590.50
Price / Free Cash Flow-34.65-2.51-4.27-2.05-24.46-139.98
ENTERPRISE VALUE METRICS
Enterprise Value115.9-16.3175.0174.1129.5117.4
Enterprise Value / Sales2.33-0.161.761.604.404.04
Enterprise Value / EBITDA53.308.36119.7626.46-2.81114.73
Enterprise Value / EBIT-36.431.95-19.27-86.34-2.62-75.87

Financials

Full Financials
Millions USD5Yr CAGR (%)Dec '21Dec '22Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue4.7%100.3103.099.2109.0120.3
Gross Income-86.5%34.722.531.939.433.5
EBITDA—85.5-2.01.56.6-38.4
EBIT—77.6-8.4-9.1-2.0-50.1
Net Income—60.4-8.9-12.2-5.1-52.6
EPS (Diluted)—3.27-0.48-0.42-0.14-1.27
BALANCE SHEET
Cash & ST Inv-46.3%78.866.445.413.56.6
Total Assets5.6%185.4181.2235.5284.4230.6
Total Liabilities13.2%38.141.257.167.162.6
Total Shareholder Equity3.3%147.3140.0178.4217.3168.0
CASH FLOW
Net Operating Cash Flow—26.0-6.1-16.710.5-2.5
Cap Ex8.4%-6.2-8.9-27.5-85.2-8.6
Free Cash Flow—19.8-15.0-44.2-74.7-11.1

Enterprise Value Bridge

Millions USD18 Nov '26
Price (As of 18 Nov '26)2.86
Basic Shares42.93
Market Cap122.6
Diluted Shares42.95
Fully Diluted Shares Outstanding42.95
Fully Diluted Market Cap122.6
+Consolidated Debt16.6
−In-the-Money Convertible Debt—
+Capital Leases7.6
+Operating Leases—
−Cash & Equivalents-7.8
−Short-term Investments-
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest-
+Pension Liabilities—
Enterprise Value131.4

Segment data

Revenue

by Geography

  • United States93%
  • Canada7%

Related companies

Element Solutions Inc

ESI US

Cabot Corp

CBT US

Wd 40 Co

WDFC US

Flotek Industries Inc/cn/

FTK US

ASP Isotopes Inc.

ASPI US

Orion S.A.

OEC US

NEXT-ChemX Corporation.

CHMX US

PV Nano Cell, Ltd.

PVNNF US

Versum Materials, Inc.

VSM XS